Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma

Toni Choueiri shared a post on X about a recent paper by Brian Shuch et al. published in The Lancet Oncology.

“[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial”

Authors: Brian Shuch, Allan Pantuck, Jean-Christophe Bernhard, Colin Hayward, Peter Mulders et al.

“[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial — Congrats ⁦Brian Shuch and Zircon team for this ⁦The Lancet Oncology innovative paper in diagnostics!”

Source: Toni Choueiri/X

More posts featuring Toni Choueiri on oncodaily.com

Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.

Brian Shuch is the director of Kidney Cancer Program and Henry Alvin & Carrie L. Meinhardt Chair for Kidney Cancer Research at UCLA Institute of Urologic Oncology. Previously, he was an Associate Professor of Urologic Oncology at Yale New Haven Hospital. He completed his fellowship in Urologic Oncology from NCI. He is on the NCCN Kidney Cancer guideline panel and the VHL Family Alliance Renal Cancer Committee.